Moethu Win, MD
Cardiovascular Disease · Zephyrhills, FLNPI 1063525285
Payments from drug & device makers
Across 382 payments — averaging $34.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Philips North America LLC$2K
- Inari Medical, Inc.$1K
- Boston Scientific$848
- Penumbra, Inc.$718
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$576
- plus $4K from 32 others
What the payments were for
- Travel & lodging$1,56412%
- Food & beverage$11,69888%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 133 | $4,206 |
| Philips North America LLC | 44 | $1,532 |
| Inari Medical, Inc. | 14 | $1,118 |
| Boston Scientific | 15 | $848 |
| Penumbra, Inc. | 3 | $718 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $576 |
| Cardiovascular Systems Inc. | 21 | $503 |
| Biotronik Inc. | 20 | $408 |
| Bard Peripheral Vascular, Inc. | 3 | $367 |
| Stryker | 7 | $329 |
| Boehringer Ingelheim | 11 | $279 |
| Abbott | 11 | $231 |
| Johnson & Johnson | 7 | $215 |
| Novartis | 9 | $179 |
| Siemens Medical Solutions USA, Inc. | 4 | $176 |
| Abiomed | 2 | $170 |
| Cvrx, Inc. | 2 | $155 |
| Teleflex LLC | 1 | $137 |
| Amarin Pharma, Inc. | 6 | $130 |
| AstraZeneca | 7 | $122 |
| Canon Medical Systems USA, Inc. | 2 | $104 |
| Kestra Medical Technology Services, Inc. | 3 | $101 |
| Astellas Pharma US Inc | 2 | $91 |
| Pfizer | 4 | $73 |
| Edwards Lifesciences | 2 | $70 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Shockwave Medical, Inc | 2 | $56 |
| Baylis Medical Company Inc | 1 | $51 |
| Cook Medical LLC | 3 | $48 |
| Bardy Diagnostics, Inc. | 4 | $47 |
| Amgen | 3 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Merck | 2 | $36 |
| Lundbeck LLC | 2 | $33 |
| Cardinal Health 200 LLC | 1 | $24 |
| Angiodynamics, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$879
- CT THROMBECTOMY SYSTEM KIT$879
- ELLIPSYS VASCULAR ACCESS SYSTEM$825
- RUBY Coil$702
- Crosser iQ$353
- Reveal LINQ$314
- Pulsar-18 T3$282
- Coronary Orbital Atherectomy System$243
- Peripheral Orbital Atherectomy System$243
- HawkOne$226
- IGT D Peripheral$223
- GENERAL ATHERECTOMY$221
- EKOSONIC$164
- FlowTriever$147
- Barostim Neo System$141
- LINQ II$139
- XARELTO$124
- JARDIANCE$122
- LifeVest$119
- CoreValve Evolut$102
How this compares
$13,340 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 155 | $139,059 |
| XareltoRivaroxaban | 37 | $35,936 |
| JardianceEmpagliflozin | 30 | $33,587 |
| FarxigaDapagliflozin Propanediol | 14 | $12,845 |
| Repatha SureclickEvolocumab | 14 | $9,843 |
| ClopidogrelClopidogrel Bisulfate | 225 | $2,025 |
| Amiodarone Hcl | 57 | $1,815 |
| Metoprolol Succinate | 150 | $1,548 |
| Carvedilol | 193 | $1,498 |
| Losartan Potassium | 156 | $1,102 |
| Atorvastatin Calcium | 181 | $1,028 |
| Amlodipine Besylate | 162 | $1,024 |
| Rosuvastatin Calcium | 64 | $998 |
| Metoprolol Tartrate | 148 | $982 |
| Ranolazine ErRanolazine | 13 | $970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $73 | $139,059155 claims |
| Johnson & JohnsonXarelto | $215 | $35,93637 claims |
| Boehringer IngelheimJardiance | $279 | $33,58730 claims |
| AstraZenecaFarxiga | $122 | $12,84514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Zephyrhills
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
- Duccio BaldariWellington$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.